{
  "pmcid": "6815674",
  "sha256": "1f46a2100bb99ae3af64edf5909905e99bfc756b7bd8fb7e85c5eebc1ed3c0e0",
  "timestamp_utc": "2025-11-10T00:03:09.517334+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.638223954949101,
    "reading_ease": 34.40183235867448,
    "word_count": 243
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of cHuR as a Predictive Marker for Chemotherapy Response in Pancreatic Ductal Adenocarcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either gemcitabine (GEM) or 5-fluorouracil (5-FU) as adjuvant monotherapy."
      },
      "Participants": {
        "score": 2,
        "evidence": "379 PDA patients from the European Study Group of Pancreatic Cancer-3 trial."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either gemcitabine (GEM) or 5-fluorouracil (5-FU) as adjuvant monotherapy."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess cytoplasmic HuR (cHuR) as a predictive marker for chemotherapy response in patients with resected pancreatic ductal adenocarcinoma (PDA)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was disease-free survival (DFS), measured over a specified timeframe."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not detailed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not specified."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "379 PDA patients from the European Study Group of Pancreatic Cancer-3 trial."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "patients with high cHuR expression had significantly greater median DFS with 5-FU compared to GEM (20.1 months, CI: 8.3–36.4 vs 10.9 months, CI: 7.5–14.2; P = 0.04)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Trial registration and funding details were not provided."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}